Metabolism and Disposition Kinetics of Nicotine

Nicotine is of importance as the addictive chemical in tobacco, pharmacotherapy for smoking cessation, a potential medication for several diseases, and a useful probe drug for phenotyping cytochrome P450 2A6 (CYP2A6). We review current knowledge about the metabolism and disposition kinetics of nicotine, some other naturally occurring tobacco alkaloids, and nicotine analogs that are under development as potential therapeutic agents. The focus is on studies in humans, but animal data are mentioned when relevant to the interpretation of human data. The pathways of nicotine metabolism are described in detail. Absorption, distribution, metabolism, and excretion of nicotine and related compounds are reviewed. Enzymes involved in nicotine metabolism including cytochrome P450 enzymes, aldehyde oxidase, flavin-containing monooxygenase 3, amine N-methyltransferase, and UDP-glucuronosyltransferases are represented, as well as factors affecting metabolism, such as genetic variations in metabolic enzymes, effects of diet, age, gender, pregnancy, liver and kidney diseases, and racial and ethnic differences. Also effects of smoking and various inhibitors and inducers, including oral contraceptives, on nicotine metabolism are discussed. Due to the significance of the CYP2A6 enzyme in nicotine clearance, special emphasis is given to the effects and population distributions of CYP2A6 alleles and the regulation of CYP2A6 enzyme.

[1]  R. T. Fowler.  A redetermination of the ionization constants of nicotine , 2007 .

[2]  N. Benowitz,et al.  Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine , 2005, Clinical pharmacology and therapeutics.

[3]  Jun-yan Hong,et al.  METABOLISM OF NICOTINE AND COTININE BY HUMAN CYTOCHROME P450 2A13 , 2005, Drug Metabolism and Disposition.

[4]  W. S. Caldwell,et al.  Comparison of measured and FTC-predicted nicotine uptake in smokers , 1995, Psychopharmacology.

[5]  K. Kudo,et al.  Simultaneous determination of nicotine and cotinine in various human tissues using capillary gas chromatography/mass spectrometry , 1994, International Journal of Legal Medicine.

[6]  M. Fukumoto.  Nicotine and cotinine , 2005 .

[7]  C. Feyerabend,et al.  Nasal nicotine spray: a rapid nicotine delivery system , 2005, Psychopharmacology.

[8]  H. McLeod,et al.  A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo , 2004, Clinical pharmacology and therapeutics.

[9]  R. Tyndale,et al.  Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. , 2004, Pharmacogenetics.

[10]  N. Benowitz,et al.  Mentholated Cigarette Smoking Inhibits Nicotine Metabolism , 2004, Journal of Pharmacology and Experimental Therapeutics.

[11]  N. Benowitz,et al.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity , 2004, Clinical pharmacology and therapeutics.

[12]  M. Ingelman-Sundberg,et al.  Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). , 2004, Pharmacogenetics.

[13]  Kyle Christian,et al.  Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene. , 2004, Molecular pharmacology.

[14]  D. Greenblatt,et al.  Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. , 2004, Pharmacogenetics.

[15]  M. Nishijo,et al.  Effects of chronic exposure to low-level cadmium on renal tubular function and CYP2A6-mediated coumarin metabolism in healthy human subjects. , 2004, Toxicology letters.

[16]  M. Lang,et al.  Acute cadmium chloride administration induces hepatic and renal CYP2A5 mRNA, protein and activity in the mouse: involvement of transcription factor NRF2. , 2004, Toxicology letters.

[17]  M. Ingelman-Sundberg,et al.  A nicotine C‐oxidase gene (CYP2A6) polymorphism important for promoter activity , 2004, Human mutation.

[18]  Xiaodong Zhang,et al.  Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. , 2004, Biochemical pharmacology.

[19]  N. Benowitz,et al.  Oral contraceptives induce CYP2A6 activity and accelerate nicotine metabolism , 2004 .

[20]  P. Peeters,et al.  Pharmacokinetics and safety of mirtazapine in caucasian and japanese young healthy male volunteers , 2004 .

[21]  K. Cummings,et al.  Epidemiology of menthol cigarette use. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[22]  Jia-Long Fang,et al.  Correlation between UDP-Glucuronosyltransferase Genotypes and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Glucuronidation Phenotype in Human Liver Microsomes , 2004, Cancer Research.

[23]  G. Neurath.  Aspects of the oxidative metabolism of nicotine , 1994, The clinical investigator.

[24]  S. Nasirov,et al.  Anabasine hydrochloride — A new antismoking agent , 1978, Pharmaceutical Chemistry Journal.

[25]  F. Kratz.  Coumarin-7-hydroxylase activity in microsomes from needle biopsies of normal and diseased human liver , 1976, European Journal of Clinical Pharmacology.

[26]  M. Bende,et al.  Absolute bioavailability of nicotine applied to different nasal regions , 2004, European Journal of Clinical Pharmacology.

[27]  O. Pelkonen,et al.  Interindividual variability of coumarin 7-hydroxylation in a Turkish population , 2004, European Journal of Clinical Pharmacology.

[28]  R. Obach,et al.  Potent inhibition of human liver aldehyde oxidase by raloxifene. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[29]  K. Jain.  Modulators of nicotinic acetylcholine receptors as analgesics. , 2004, Current opinion in investigational drugs.

[30]  H. Sigusch,et al.  Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers , 2004, European Journal of Clinical Pharmacology.

[31]  R. Frecker,et al.  Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans , 2004, European Journal of Clinical Pharmacology.

[32]  J. Fourtillan,et al.  Effect of ponsinomycin on cyclosporin pharmacokinetics , 2004, European Journal of Clinical Pharmacology.

[33]  P. Daenens,et al.  Kinetics of cotinine after oral and intravenous administration to man , 2004, European Journal of Clinical Pharmacology.

[34]  Rosette Lidereau,et al.  Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma , 2004, Breast Cancer Research.

[35]  B. Ring,et al.  Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression , 2003, Journal of Pharmacology and Experimental Therapeutics.

[36]  R. Tyndale,et al.  The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[37]  C. B. Pickett,et al.  Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. , 2003, Annual review of pharmacology and toxicology.

[38]  J. Casida,et al.  Selective toxicity of neonicotinoids attributable to specificity of insect and mammalian nicotinic receptors. , 2003, Annual review of entomology.

[39]  W. Tan,et al.  Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. , 2003, Cancer research.

[40]  S. Murphy,et al.  N-glucuronidation of trans-3'-hydroxycotinine by human liver microsomes. , 2003, Chemical research in toxicology.

[41]  S. Murphy,et al.  N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[42]  T. Nolin,et al.  Hepatic drug metabolism and transport in patients with kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  H. Yamazaki,et al.  Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). , 2003, Pharmacogenetics.

[44]  I. Cascorbi.  Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication , 2003, European journal of clinical investigation.

[45]  K. Strahs,et al.  Pharmacokinetics of a nicotine polacrilex lozenge. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[46]  Qing-Yu Zhang,et al.  Immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa. , 2003, Biochemical pharmacology.

[47]  C. Pomerleau,et al.  Nicotine metabolite ratio as a predictor of cigarette consumption. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[48]  Stephen S. Hecht,et al.  Tobacco carcinogens, their biomarkers and tobacco-induced cancer , 2003, Nature Reviews Cancer.

[49]  C. Guillemette,et al.  Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs , 2003, Journal of Pharmacology and Experimental Therapeutics.

[50]  C. Derauf,et al.  Agreement between maternal self-reported ethanol intake and tobacco use during pregnancy and meconium assays for fatty acid ethyl esters and cotinine. , 2003, American journal of epidemiology.

[51]  F. Berthou,et al.  Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine. , 2003, Toxicology letters.

[52]  E. Domino,et al.  Comparative American and Japanese tobacco smoke uptake parameters after overnight tobacco deprivation , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[53]  M. Caggana,et al.  Single nucleotide polymorphisms of the human cyp2a13 gene: evidence for a null allele. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[54]  A. Poso,et al.  Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. , 2003, Toxicology in vitro : an international journal published in association with BIBRA.

[55]  J. Goldstein,et al.  Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. , 2003, Molecular pharmacology.

[56]  J. Pankow,et al.  Percent free base nicotine in the tobacco smoke particulate matter of selected commercial and reference cigarettes. , 2003, Chemical research in toxicology.

[57]  Xiaodong Zhang,et al.  Inhibition of human liver microsomal (S)-nicotine oxidation by (-)-menthol and analogues. , 2003, Chemical research in toxicology.

[58]  S. Tokudome,et al.  Effects of polymorphism in Promoter Region of Human CYP2A6 Gene (CYP2A6*9) on Expression Level of Messenger Ribonucleic Acid and Enzymatic Activity In Vivo and In Vitro , 2003, Clinical pharmacology and therapeutics.

[59]  D. Mash,et al.  Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.

[60]  T. Thum,et al.  Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[61]  R. Tyndale,et al.  Decreasing smoking behaviour and risk through CYP2A6 inhibition. , 2003, Drug discovery today.

[62]  R. Obach,et al.  Ziprasidone Metabolism, Aldehyde Oxidase, and Clinical Implications , 2003, Journal of clinical psychopharmacology.

[63]  R. Tyndale,et al.  CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. , 2003, Pharmacogenetics.

[64]  L. Moore,et al.  Identification of a Novel Human Constitutive Androstane Receptor (CAR) Agonist and Its Use in the Identification of CAR Target Genes* , 2003, The Journal of Biological Chemistry.

[65]  C. Jepson,et al.  Individual differences in nicotine intake per cigarette. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[66]  Hongbing Wang,et al.  Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[67]  Sharon Miksys,et al.  Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics , 2003, British journal of pharmacology.

[68]  Liang-Shang Gan,et al.  Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[69]  Ricarda Thier,et al.  The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine , 2003, International archives of occupational and environmental health.

[70]  A. Burnett,et al.  Safety, Pharmacokinetics, and Effects on Cognitive Function of Multiple Doses of GTS-21 in Healthy, Male Volunteers* , 2003, Neuropsychopharmacology.

[71]  J. Tredger,et al.  Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[72]  S. Anttila,et al.  Regulation of CYP3A5 by Glucocorticoids and Cigarette Smoke in Human Lung-Derived Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[73]  L. Lash,et al.  Human Kidney Flavin-Containing Monooxygenases and Their Potential Roles in Cysteine S-Conjugate Metabolism and Nephrotoxicity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[74]  A. Poso,et al.  More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[75]  R. Tyndale,et al.  Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. , 2003, Molecular pharmacology.

[76]  M. Nakajima,et al.  Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[77]  E. Hawes,et al.  Microsomal N-glucuronidation of nicotine and cotinine: human hepatic interindividual, human intertissue, and interspecies hepatic variation. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[78]  R. Tyndale,et al.  CYP2A6 genetic variation and potential consequences. , 2002, Advanced drug delivery reviews.

[79]  M. Nakajima,et al.  Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. , 2002, British journal of clinical pharmacology.

[80]  R. Tyndale,et al.  Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[81]  G. Scherer,et al.  Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography-tandem mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[82]  J. Cashman,et al.  Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[83]  L. Dwoskin,et al.  Total Cotinine in Plasma: A Stable Biomarker for Exposure to Tobacco Smoke , 2002, Journal of clinical psychopharmacology.

[84]  M. Ingelman-Sundberg,et al.  Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity , 2002, Human mutation.

[85]  M. Quik,et al.  Nicotine and nicotinic receptors; relevance to Parkinson's disease. , 2002, Neurotoxicology.

[86]  E. Hawes,et al.  N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[87]  Jun Yokota,et al.  Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[88]  Sharon Miksys,et al.  Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics , 2002, Journal of neurochemistry.

[89]  Hideyuki Saito,et al.  Transport Mechanisms of Nicotine across the Human Intestinal Epithelial Cell Line Caco-2 , 2002, Journal of Pharmacology and Experimental Therapeutics.

[90]  P. Steenkamp,et al.  Accidental fatal poisoning by Nicotiana glauca: identification of anabasine by high performance liquid chromatography/photodiode array/mass spectrometry. , 2002, Forensic science international.

[91]  E. Richter,et al.  New sources of dietary myosmine uptake from cereals, fruits, vegetables, and milk. , 2002, Journal of agricultural and food chemistry.

[92]  H. Saito,et al.  cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. , 2002, Journal of the American Society of Nephrology : JASN.

[93]  R. Zhu,et al.  Phenotypic polymorphism of CYP2A6 activity in a Chinese population , 2002, European Journal of Clinical Pharmacology.

[94]  Hiroshi Yamazaki,et al.  A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. , 2002, Pharmacogenetics.

[95]  T. Sueyoshi,et al.  Residue threonine 350 confers steroid hormone responsiveness to the mouse nuclear orphan receptor CAR. , 2002, Molecular pharmacology.

[96]  M. Utt,et al.  Separation and surveys of proteins of Helicobacter pylori. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[97]  R. Peng,et al.  In vitro metabolic characteristics of cytochrome P-450 2A6 in Chinese liver microsomes. , 2002, Acta pharmacologica Sinica.

[98]  N. Benowitz,et al.  Accelerated metabolism of nicotine and cotinine in pregnant smokers. , 2002, The Journal of pharmacology and experimental therapeutics.

[99]  M. Lang,et al.  CYP2A6/2A7 and CYP2E1 expression in human oesophageal mucosa: regional and inter-individual variation in expression and relevance to nitrosamine metabolism. , 2002, Carcinogenesis.

[100]  H. Yamazaki,et al.  Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females. , 2002, Pharmacogenetics.

[101]  C. Sweeney,et al.  CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[102]  Philip Lazarus,et al.  Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[103]  E. Sellers,et al.  Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. , 2002, Journal of women's health & gender-based medicine.

[104]  D. Balfour.  The Neurobiology of Tobacco Dependence: A Commentary , 2002, Respiration.

[105]  R. Tyndale,et al.  Genetic Variation in CYP2A6-Mediated Nicotine Metabolism Alters Smoking Behavior , 2002, Therapeutic drug monitoring.

[106]  E. Perez-stable,et al.  Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. , 2002, Journal of the National Cancer Institute.

[107]  R. Tyndale,et al.  An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. , 2002, Biochemical and biophysical research communications.

[108]  J. Pascussi,et al.  Transcriptional Regulation of CYP2C9 Gene , 2002, The Journal of Biological Chemistry.

[109]  K. Iwahashi,et al.  EFFECTS OF WHOLE DELETION OF CYP2A6 ON NICOTINE METABOLISM IN HUMANS , 2002, Drug and chemical toxicology.

[110]  M. Nakajima,et al.  INTERINDIVIDUAL DIFFERENCES IN NICOTINE METABOLISM AND GENETIC POLYMORPHISMS OF HUMAN CYP2A6 , 2002, Drug metabolism reviews.

[111]  Hannu Raunio,et al.  Expression and Regulation of Xenobiotic-Metabolizing Cytochrome P450 (CYP) Enzymes in Human Lung , 2002, Critical reviews in toxicology.

[112]  J. Pascussi,et al.  ROLE OF GLUCOCORTICOID RECEPTOR AND CONSTITUTIVE ANDROSTANE RECEPTOR , 2002 .

[113]  H. Yamazaki,et al.  Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. , 2002, Drug Metabolism and Pharmacokinetics.

[114]  D. Sparks,et al.  The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease. , 2002, Journal of Alzheimer's disease : JAD.

[115]  J. Mackay,et al.  The Tobacco Atlas , 2002 .

[116]  J. Pascussi,et al.  Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. , 2001, European journal of biochemistry.

[117]  N. Benowitz,et al.  Deficient C‐oxidation of nicotine continued , 2001, Clinical pharmacology and therapeutics.

[118]  W. Henderson,et al.  QTc prolongation and drugs , 2001, Clinical pharmacology and therapeutics.

[119]  Michael D. Johnson,et al.  Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. , 2001, The Journal of pharmacology and experimental therapeutics.

[120]  G. Bepler,et al.  Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. , 2001, Toxicology.

[121]  J. Pankow.  A consideration of the role of gas/particle partitioning in the deposition of nicotine and other tobacco smoke compounds in the respiratory tract. , 2001, Chemical research in toxicology.

[122]  O Pelkonen,et al.  Polymorphisms of CYP2A6 and its practical consequences. , 2001, British journal of clinical pharmacology.

[123]  J. Markowitz,et al.  Drug Glucuronidation in Clinical Psychopharmacology , 2001, Journal of clinical psychopharmacology.

[124]  J. Gilmore,et al.  Identification of a 43-kDa protein in human liver cytosol that binds to the 3'-untranslated region of CYP2A6 mRNA. , 2001, Biochemical pharmacology.

[125]  R. Edwards,et al.  Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples. , 2001, Biochemical pharmacology.

[126]  I. Phillips,et al.  Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. , 2001, Biochemical pharmacology.

[127]  Y. Moriwaki,et al.  Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. , 2001, Histology and histopathology.

[128]  T. Kamataki,et al.  Screening of organosulfur compounds as inhibitors of human CYP2A6. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[129]  M. Ingelman-Sundberg,et al.  Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. , 2001, Biochemical and biophysical research communications.

[130]  T Yamamoto,et al.  Nicotine metabolism and CYP2A6 allele frequencies in Koreans. , 2001, Pharmacogenetics.

[131]  R. Tyndale,et al.  Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[132]  P. Selby,et al.  Heavily Smoking Women Who Cannot Quit in Pregnancy: Evidence of Pharmacokinetic Predisposition , 2001, Therapeutic drug monitoring.

[133]  K. Kitagawa,et al.  Individual differences in urinary cotinine levels in Japanese smokers: relation to genetic polymorphism of drug-metabolizing enzymes. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[134]  S. Hecht,et al.  Consumption of watercress fails to alter coumarin metabolism in humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[135]  M. Kitagawa,et al.  CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic Activity* , 2001, The Journal of Biological Chemistry.

[136]  M. Eichelbaum,et al.  Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. , 2001, Pharmacogenetics.

[137]  T. Yaksh,et al.  A-85380 and epibatidine each interact with disparate spinal nicotinic receptor subtypes to achieve analgesia and nociception. , 2001, The Journal of pharmacology and experimental therapeutics.

[138]  R. Tyndale,et al.  Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[139]  T. Kamataki,et al.  A novel single nucleotide polymorphism altering stability and activity of CYP2a6. , 2001, Biochemical and biophysical research communications.

[140]  O. Pelkonen,et al.  In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[141]  H. Issaq,et al.  Nicotine metabolism and CYP2D6 phenotype in smokers. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[142]  J. Pascussi,et al.  Induction of CYP2C genes in human hepatocytes in primary culture. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[143]  M. Oscarson.  Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[144]  M. Jarvis,et al.  Nicotine yield from machine-smoked cigarettes and nicotine intakes in smokers: evidence from a representative population survey. , 2001, Journal of the National Cancer Institute.

[145]  Hiroshi Yamamoto,et al.  Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans , 2001, Clinical pharmacology and therapeutics.

[146]  A. Hansson,et al.  Pharmacokinetics of nicotine in healthy elderly people , 2001, Clinical pharmacology and therapeutics.

[147]  N. Benowitz,et al.  Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. , 2001, British journal of clinical pharmacology.

[148]  P. Gow,et al.  Neonatal hepatic drug elimination. , 2001, Pharmacology & toxicology.

[149]  N. Benowitz,et al.  Risks and Benefits of Nicotine to Aid Smoking Cessation in Pregnancy , 2001, Drug safety.

[150]  E. Lunell,et al.  Pharmacokinetic investigation of a nicotine sublingual tablet , 2001, European Journal of Clinical Pharmacology.

[151]  O. Niemelä,et al.  Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. , 2000, Journal of hepatology.

[152]  J. Pascussi,et al.  Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. , 2000, Molecular pharmacology.

[153]  S. Hecht,et al.  2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[154]  S. Murphy,et al.  O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[155]  R. Poland,et al.  Effect of cigarette smoking on coumarin metabolism in humans. , 2000, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[156]  T. Kawamoto,et al.  Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene. , 2000, Molecular endocrinology.

[157]  M. Loriot,et al.  Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. , 2000, Pharmacogenetics.

[158]  S. Shiffman,et al.  A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches , 2000, Pharmacology Biochemistry and Behavior.

[159]  O. Pelkonen,et al.  CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[160]  A. Watt,et al.  Determination of the in vitro metabolism of (+)- and (-)-epibatidine. , 2000, Journal of chromatography. A.

[161]  R. Tyndale,et al.  Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. , 2000, Molecular pharmacology.

[162]  Jun-yan Hong,et al.  Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. , 2000, Cancer research.

[163]  E. Lunell,et al.  Pharmacokinetics of nicotine in kidney failure , 2000, Clinical pharmacology and therapeutics.

[164]  J. Pascussi,et al.  Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. , 2000, Biochemical and biophysical research communications.

[165]  R. Tyndale,et al.  Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking , 2000, Clinical pharmacology and therapeutics.

[166]  P. Jacob,et al.  Clinical pharmacology of oral cotinine. , 2000, Drug and alcohol dependence.

[167]  W. Tassaneeyakul,et al.  Inhibition selectivity of grapefruit juice components on human cytochromes P450. , 2000, Archives of biochemistry and biophysics.

[168]  N. Benowitz,et al.  Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism , 2000, Clinical pharmacology and therapeutics.

[169]  V. Ganapathy,et al.  Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. , 2000, Biochimica et biophysica acta.

[170]  P. Robertson,et al.  In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[171]  A. Bienert,et al.  Influence of smoking on cotinine and caffeine plasma levels in patients with alcoholic liver cirrhosis. , 2000, European journal of medical research.

[172]  L. Moore,et al.  Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands* , 2000, The Journal of Biological Chemistry.

[173]  N. Benowitz,et al.  Nicotine metabolism and elimination kinetics in newborns , 2000, Clinical pharmacology and therapy.

[174]  S. Levy,et al.  Fatal poisoning from Nicotiana glauca leaves: identification of anabasine by gas-chromatography/mass spectrometry. , 2000, Journal of forensic sciences.

[175]  K. Castagnoli,et al.  Studies on the in vivo biotransformation of the tobacco alkaloid beta-nicotyrine. , 2000, Chemical research in toxicology.

[176]  O. Pelkonen,et al.  CYP2A6: a human coumarin 7-hydroxylase. , 2000, Toxicology.

[177]  S. Hecht,et al.  Enantiomeric composition of N'-nitrosonornicotine and N'-nitrosoanatabine in tobacco. , 2000, Carcinogenesis.

[178]  R. West,et al.  A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler , 2000, Psychopharmacology.

[179]  K. Husgafvel‐Pursiainen,et al.  CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. , 2000, Pharmacogenetics.

[180]  Hiroshi Yamamoto,et al.  Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans , 2000, Clinical pharmacology and therapeutics.

[181]  Y. Berger,et al.  Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[182]  N. Benowitz,et al.  Nicotine‐mecamylamine interactions , 1999, Clinical pharmacology and therapeutics.

[183]  M. Bootman,et al.  13th International Symposium on Microsomes and Drug Oxidations , 2000 .

[184]  J. Spence,et al.  Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.

[185]  Reducing tobacco use: a report of the Surgeon General--executive summary. , 2000, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[186]  E. Kharasch,et al.  Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[187]  J. Wahren,et al.  Site of nicotine absorption from a vapour inhaler – comparison with cigarette smoking , 2000, European Journal of Clinical Pharmacology.

[188]  E. Perez-stable,et al.  Ethnic differences in N-glucuronidation of nicotine and cotinine. , 1999, The Journal of pharmacology and experimental therapeutics.

[189]  T. Sawada,et al.  [Medical therapy in ulcerative colitis]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.

[190]  R. Weinshilboum,et al.  Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization. , 1999, Genomics.

[191]  O Pelkonen,et al.  Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism , 1999, FEBS letters.

[192]  S. Hecht,et al.  Effects of watercress consumption on urinary metabolites of nicotine in smokers. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[193]  R. Coleman,et al.  Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. , 1999, Drug and alcohol dependence.

[194]  K. Kitagawa,et al.  The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. , 1999, Biochemical and biophysical research communications.

[195]  T. Kamataki,et al.  Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. , 1999, Journal of biochemistry.

[196]  E. Leitner,et al.  Determination of the nicotine content of various edible nightshades (Solanaceae) and their products and estimation of the associated dietary nicotine intake. , 1999, Journal of agricultural and food chemistry.

[197]  L. Mellick,et al.  Neuromuscular blockade after ingestion of tree tobacco (Nicotiana glauca). , 1999, Annals of emergency medicine.

[198]  D. Hum,et al.  The Monkey and Human Uridine Diphosphate-Glucuronosyltransferase UGT1A9, Expressed in Steroid Target Tissues, Are Estrogen-Conjugating Enzymes. , 1999, Endocrinology.

[199]  D. Dempsey,et al.  The detection of cotinine in hydrolyzed meconium samples. , 1999, Forensic science international.

[200]  S. Anttila,et al.  Expression of CYP2A genes in human liver and extrahepatic tissues. , 1999, Biochemical pharmacology.

[201]  S. Murphy,et al.  Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. , 1999, Chemical research in toxicology.

[202]  K. Igarashi,et al.  Studies on the pyrrolinone metabolites derived from the tobacco alkaloid 1-methyl-2-(3-pyridinyl)pyrrole (beta-nicotyrine). , 1999, Chemical research in toxicology.

[203]  N. Benowitz,et al.  Drug Interactions with Tobacco Smoking , 1999, Clinical pharmacokinetics.

[204]  P. Beaune,et al.  Human CYP2B6: expression, inducibility and catalytic activities. , 1999, Pharmacogenetics.

[205]  C. Stockmeier,et al.  Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. , 1999, The Journal of pharmacology and experimental therapeutics.

[206]  J. Nezu,et al.  Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. , 1999, The Journal of pharmacology and experimental therapeutics.

[207]  N. Benowitz,et al.  Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. , 1999, American journal of public health.

[208]  K. Bock,et al.  Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[209]  M. Ingelman-Sundberg,et al.  Characterisation and PCR‐based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population , 1999, FEBS letters.

[210]  D. Beckers,et al.  Cotinine in meconium indicates risk for early respiratory tract infections , 1999, Human & experimental toxicology.

[211]  T. Kamataki,et al.  A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. , 1999, The Journal of pharmacology and experimental therapeutics.

[212]  Kiyoshi Inoue,et al.  Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes , 1999, Archives of Toxicology.

[213]  M. Manns,et al.  Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. , 1999, The Biochemical journal.

[214]  D. N. Sims,et al.  Another death due to ingestion of Nicotiana glauca. , 1999, Journal of forensic sciences.

[215]  D. Hatsukami,et al.  Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. , 1999, Cancer research.

[216]  C. Wild,et al.  Characterization of cytochrome P450 expression in human oesophageal mucosa. , 1999, Carcinogenesis.

[217]  D. Hatsukami,et al.  Quantitation of 4-oxo-4-(3-pyridyl)butanoic acid and enantiomers of 4-hydroxy-4-(3-pyridyl)butanoic acid in human urine: A substantial pathway of nicotine metabolism. , 1999, Chemical research in toxicology.

[218]  J. Andre,et al.  Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[219]  D. Armstrong,et al.  Enantiomeric composition of nornicotine, anatabine, and anabasine in tobacco , 1999 .

[220]  S. Arneric,et al.  Neuronal nicotinic receptors : pharmacology and therapeutic opportunities , 1999 .

[221]  M. Tsai,et al.  EVIDENCE FOR THE BIOSYNTHESIS OF A GLUCURONIDE CONJUGATE OF (S)-(-)-NICOTINE, BUT NOT (SM-)-COTININE OR (±)-trans-3'- HYDROXYCOTININE BY MARMOSET HEPATIC MICROSOMES , 1999, Drug metabolism and drug interactions.

[222]  J. I. Seeman,et al.  5'-hydroxycotinine-N-oxide, a new nicotine metabolite isolated from rat urine. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[223]  R. Koeppe,et al.  Arterial/venous plasma nicotine concentrations following nicotine nasal spray , 1999, European Journal of Clinical Pharmacology.

[224]  L. Kozlowski,et al.  Filter ventilation and nicotine content of tobacco in cigarettes from Canada, the United Kingdom, and the United States , 1998, Tobacco control.

[225]  G. Koren,et al.  Transplacental transfer and biotransformation studies of nicotine in the human placental cotyledon perfused in vitro. , 1998, Life sciences.

[226]  S. Masuda,et al.  Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. , 1998, The Journal of pharmacology and experimental therapeutics.

[227]  W. Thilly,et al.  Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells. , 1998, Carcinogenesis.

[228]  D. G. McCarver,et al.  A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. , 1998, Toxicology and applied pharmacology.

[229]  D. Altman,et al.  Green tobacco sickness , 1998, Tobacco control.

[230]  T. Rao,et al.  Conformationally restricted analogues of nicotine and anabasine. , 1998, Bioorganic & medicinal chemistry letters.

[231]  L. Palmer,et al.  The elimination half-life of urinary cotinine in children of tobacco-smoking mothers. , 1998, Pulmonary pharmacology & therapeutics.

[232]  M. Takano,et al.  Distinct characteristics of transcellular transport between nicotine and tetraethylammonium in LLC-PK1 cells. , 1998, The Journal of pharmacology and experimental therapeutics.

[233]  E. Perez-stable,et al.  Nicotine metabolism and intake in black and white smokers. , 1998, JAMA.

[234]  G. Giovino,et al.  Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. , 1998, JAMA.

[235]  D. Hatsukami,et al.  Effects of cotinine on cigarette self-administration , 1998, Psychopharmacology.

[236]  E. Perry,et al.  Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use , 1998, Neuroscience.

[237]  E. Richter,et al.  Occurrence of the Tobacco Alkaloid Myosmine in Nuts and Nut Products of Arachus hypogaea and Corylus avellana , 1998 .

[238]  S. Hecht,et al.  Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. , 1998, Chemical research in toxicology.

[239]  Y. Funae,et al.  A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). , 1998, Pharmacogenetics.

[240]  G. Hageman,et al.  Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[241]  I. Baranowska,et al.  Determination of nicotine, cotinine and caffeine in meconium using high-performance liquid chromatography. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[242]  M. Manns,et al.  Expression of the UDP-glucuronosyltransferase 1A Locus in Human Colon , 1998, The Journal of Biological Chemistry.

[243]  B. Burchell,et al.  Drug glucuronidation by human renal UDP-glucuronosyltransferases. , 1998, Biochemical pharmacology.

[244]  M. Jarvis,et al.  Variations in cotinine levels in smokers during and after pregnancy. , 1998, American journal of obstetrics and gynecology.

[245]  J. Gustafsson,et al.  Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties. , 1998, The Journal of clinical endocrinology and metabolism.

[246]  B. Ludes,et al.  Nicotine monitoring in sweat with a sweat patch. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[247]  D. Hatsukami,et al.  Cotinine: effects with and without nicotine , 1998, Psychopharmacology.

[248]  Y. Soini,et al.  Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma , 1998, Hepatology.

[249]  D. Donnelly-roberts,et al.  Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. , 1998, Science.

[250]  S. Ralapati,et al.  Application of high‐performance capillary electrophoresis to the quantitative analysis of nicotine and profiling of other alkaloids in ATF‐regulated tobacco products , 1998, Electrophoresis.

[251]  D. Armstrong,et al.  Enantiomeric Composition of Nicotine in Smokeless Tobacco, Medicinal Products, and Commercial Reagents , 1998 .

[252]  E. Callaway,et al.  Effects of cotinine on information processing in nonsmokers , 1998, Psychopharmacology.

[253]  J K Lynch,et al.  Neuronal nicotinic acetylcholine receptors as targets for drug discovery. , 1997, Journal of medicinal chemistry.

[254]  O. Pelkonen,et al.  Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. , 1997, Toxicology.

[255]  K. Ahijevych,et al.  Nicotine dependence and smoking topography among black and white women. , 1997, Research in nursing & health.

[256]  W. Trager,et al.  Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[257]  S. Imaoka,et al.  A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. , 1997, Life sciences.

[258]  A. Li,et al.  Quantitative reverse transcriptase/PCR assay for the measurement of induction in cultured hepatocytes. , 1997, Chemico-biological interactions.

[259]  N. Benowitz,et al.  Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine , 1997, Clinical pharmacology and therapeutics.

[260]  A. Zinsmeister,et al.  A dose‐ranging pharmacokinetic study of nicotine tartrate following single‐dose delayed‐release oral and intravenous administration , 1997, Alimentary pharmacology & therapeutics.

[261]  N. Chauret,et al.  In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[262]  D. Donnelly-roberts,et al.  ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. , 1997, The Journal of pharmacology and experimental therapeutics.

[263]  R. Tyndale,et al.  A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.

[264]  J. Idle,et al.  A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. , 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[265]  D. Hatsukami,et al.  Safety of Cotinine in Humans: Physiologic, Subjective, and Cognitive Effects , 1997, Pharmacology Biochemistry and Behavior.

[266]  P. Kemp,et al.  Postmortem distribution of nicotine and cotinine from a case involving the simultaneous administration of multiple nicotine transdermal systems. , 1997, Journal of analytical toxicology.

[267]  E. London,et al.  [125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[268]  A. C. Collins,et al.  Effect of Smoking History on [ 3 H]nicotine Binding in Human Postmortem Brain 1 , 2022 .

[269]  N. Benowitz,et al.  Cotinine effects on nicotine metabolism , 1997, Clinical pharmacology and therapeutics.

[270]  A. Zinsmeister,et al.  Pharmacokinetics of Nicotine Tartrate after Single‐Dose Liquid Enema, Oral, and Intravenous Administration , 1997, Journal of clinical pharmacology.

[271]  G. Andersson,et al.  The influence of cigarette consumption and smoking machine yields of tar and nicotine on the nicotine uptake and oral mucosal lesions in smokers. , 1997, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[272]  D. Desai,et al.  Evidence for endogenous formation of tobacco-specific nitrosamines in rats treated with tobacco alkaloids and sodium nitrite. , 1997, Carcinogenesis.

[273]  D. Hatsukami,et al.  Society for Research on Nicotine and Tobacco. , 1997, Addiction.

[274]  W. Legrum,et al.  The character of inhibition of the metabolism of 1,2-benzopyrone (coumarin) by grapefruit juice in human , 1997, European Journal of Clinical Pharmacology.

[275]  T. Rao,et al.  Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats. , 1997, The Journal of pharmacology and experimental therapeutics.

[276]  M. Bencherif,et al.  RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. , 1996, The Journal of pharmacology and experimental therapeutics.

[277]  Y. Funae,et al.  Role of human cytochrome P4502A6 in C-oxidation of nicotine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[278]  S. Kitamura,et al.  S‐(‐)‐nicotine‐1′‐N‐oxide reductase activity of rat liver aldehyde oxidase , 1996, Biochemistry and molecular biology international.

[279]  D Verotta,et al.  Chronopharmacokinetics of nicotine , 1996, Clinical pharmacology and therapeutics.

[280]  H. Bartsch,et al.  Induction of cytochrome P450 2A6 expression in humans by the carcinogenic parasite infection, opisthorchiasis viverrini. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[281]  R. Olmstead,et al.  Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. , 1996, Addiction.

[282]  P. Adams,et al.  (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. , 1996, Journal of medicinal chemistry.

[283]  A. Rautio,et al.  Age and CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in man. , 1996, Therapie.

[284]  N. Benowitz,et al.  The Benefits of Stopping Smoking and the Role of Nicotine Replacement Therapy in Older Patients , 1996, Drugs & aging.

[285]  G. Batist,et al.  Overexpression of Cytochrome P-450 Isoforms Involved in Aflatoxin B1 Bioactivation in Human Liver with Cirrhosis and Hepatitis , 1996, Toxicologic pathology.

[286]  E. Perez-stable,et al.  CYP2D6 phenotype and the metabolism of nicotine and cotinine. , 1996, Pharmacogenetics.

[287]  Y. Funae,et al.  Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[288]  A. Nordberg,et al.  Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography , 1996, Clinical pharmacology and therapeutics.

[289]  E. Lunell,et al.  Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler , 1996, Clinical pharmacology and therapeutics.

[290]  Y. Berger,et al.  Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[291]  N. Benowitz,et al.  Cotinine as a biomarker of environmental tobacco smoke exposure. , 1996, Epidemiologic reviews.

[292]  H. Yamazaki,et al.  Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[293]  N. Benowitz.  Pharmacology of nicotine: addiction and therapeutics. , 1996, Annual review of pharmacology and toxicology.

[294]  O. Pelkonen,et al.  Coumarin 7-hydroxylation in long-term adherents of a strict uncooked vegan diet , 1996, European Journal of Clinical Pharmacology.

[295]  E. Lunell,et al.  Transdermally administered nicotine accumulates in gastric juice , 1996, European Journal of Clinical Pharmacology.

[296]  M. Jarvik,et al.  Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. , 1995, Addiction.

[297]  A. D. Rodrigues,et al.  In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N'-oxidation. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[298]  S. Wrighton,et al.  In vitro-in vivo correlations of human (S)-nicotine metabolism. , 1995, Biochemical pharmacology.

[299]  S. Arneric,et al.  Characterization of [3H]ABT-418: a novel cholinergic channel ligand. , 1995, The Journal of pharmacology and experimental therapeutics.

[300]  N. Benowitz,et al.  Deficient C‐oxidation of nicotine , 1995, Clinical pharmacology and therapeutics.

[301]  S. Balabanova,et al.  [Detection of nicotine in eccrine sweat after stimulation of sweat glands during nicotine withdrawal]. , 1995, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[302]  A. Nordberg,et al.  Regional deposition of inhaled 11C‐nicotine vapor in the human airway as visualized by positron emission tomography , 1995, Clinical pharmacology and therapeutics.

[303]  S. Skerfving,et al.  Urinary cotinine in children and adults during and after semiexperimental exposure to environmental tobacco smoke. , 1995, Archives of environmental health.

[304]  D. Madlon-Kay.  Transdermal Nicotine Patches , 1995, The Journal of the American Board of Family Medicine.

[305]  N. Benowitz.  Clinical pharmacology of transdermal nicotine , 1995 .

[306]  O. Pelkonen,et al.  CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. , 1995, British journal of clinical pharmacology.

[307]  P. Clarke,et al.  Effects of Nicotine on Biological Systems II , 1995, Advances in Pharmacological Sciences.

[308]  N. Benowitz,et al.  Metabolism of nicotine to cotinine studied by a dual stable isotope method , 1994, Clinical pharmacology and therapeutics.

[309]  A. M. Collier,et al.  Cotinine Elimination and Its Use as a Biomarker in Young Children Involuntarily Exposed to Environmental Tobacco Smoke , 1994 .

[310]  O Pelkonen,et al.  Metabolic interactions of methoxsalen and coumarin in humans and mice. , 1994, Biochemical pharmacology.

[311]  F. Guengerich,et al.  Metabolic activation and carcinogen-DNA adduct detection in human larynx. , 1994, Cancer research.

[312]  A. D. Rodrigues,et al.  The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[313]  B. Eskenazi,et al.  Black-white differences in serum cotinine levels among pregnant women and subsequent effects on infant birthweight. , 1994, American journal of public health.

[314]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[315]  D. Hatsukami,et al.  Pharmacodynamic effects of cotinine in abstinent cigarette smokers , 1994, Clinical pharmacology and therapeutics.

[316]  K. Tilashalski,et al.  Assessing the nicotine content of smokeless tobacco products. , 1994, Journal of the American Dental Association.

[317]  E. Ostrea,et al.  Meconium analysis to assess fetal exposure to nicotine by active and passive maternal smoking. , 1994, The Journal of pediatrics.

[318]  R. Hurt,et al.  Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. , 1994, JAMA.

[319]  W. S. Caldwell,et al.  Direct determination of cotinine-N-glucuronide in urine using thermospray liquid chromatography/mass spectrometry. , 1994, Biological mass spectrometry.

[320]  N. Benowitz,et al.  Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. , 1994, The Journal of pharmacology and experimental therapeutics.

[321]  Y. Li,et al.  N-hydroxymethylnorcotinine, a new primary in vitro metabolite of cotinine. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[322]  N. Benowitz,et al.  Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1'-oxide. , 1993, Chemical research in toxicology.

[323]  E. Vesell,et al.  Identification of radiolabeled metabolites of nicotine in rat bile. Synthesis of S-(-)-nicotine N-glucuronide and direct separation of nicotine-derived conjugates using high-performance liquid chromatography. , 1993, Journal of chromatography.

[324]  J. Henningfield,et al.  Nicotine delivery kinetics and abuse liability. , 1993, Journal of consulting and clinical psychology.

[325]  E. Domino,et al.  The nicotine content of common vegetables. , 1993, The New England journal of medicine.

[326]  Richard D. Prather,et al.  Nicotine Pharmacokinetics of Nicoderm® (Nicotine Transdermal System) in Women and Obese Men Compared With Normal‐Sized Men , 1993, Journal of clinical pharmacology.

[327]  Imaoka Susumu,et al.  Nicotine metabolism by rat hepatic cytochrome P450s , 1993 .

[328]  J E Henningfield,et al.  Higher levels of nicotine in arterial than in venous blood after cigarette smoking. , 1993, Drug and alcohol dependence.

[329]  E. Nexo,et al.  Acute effects of smoking during modified sham feeding in duodenal ulcer patients. An analysis of nicotine, acid secretion, gastrin, catecholamines, epidermal growth factor, prostaglandin E2, and bile acids. , 1993, Scandinavian journal of gastroenterology.

[330]  D. Sparks,et al.  Immunohistochemical Localization of a Cytochrome P-450 Isozyme in Human Nasal Mucosa: Age-Related Trends , 1993, The Annals of otology, rhinology, and laryngology.

[331]  N. Benowitz,et al.  Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers , 1993, Clinical pharmacology and therapeutics.

[332]  K. Vähäkangas,et al.  Extrahepatic metabolism of nicotine and related compounds by cytochromes P450 , 1993 .

[333]  J. Wahren,et al.  Nicotine and related alkaloids : absorption, distribution, metabolism, and excretion , 1993 .

[334]  Felix Franks,et al.  In-Vitro Characterization of mCerulean3_mRuby3 as a Novel FRET Pair with Favorable Bleed-Through Characteristics , 2019, Biosensors.

[335]  N. Castagnoli,et al.  The metabolic fate of the minor tobacco alkaloids , 1993 .

[336]  Smoking cessation during previous year among adults--United States, 1990 and 1991. , 1993, MMWR. Morbidity and mortality weekly report.

[337]  E. Vesell,et al.  Variables affecting nicotine metabolism. , 1993, Pharmacology & therapeutics.

[338]  S. Imaoka,et al.  Nicotine metabolism by rat hepatic cytochrome P450s. , 1993, Biochemical pharmacology.

[339]  A. Parkinson,et al.  Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. , 1992, Archives of biochemistry and biophysics.

[340]  O Pelkonen,et al.  Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. , 1992, Pharmacogenetics.

[341]  N. Benowitz,et al.  Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. , 1992, Chemical research in toxicology.

[342]  S. Davies,et al.  Localization of cytochrome P‐450 gene expression in normal and diseased human liver by in situ hybridization of wax‐embedded archival material , 1992, Hepatology.

[343]  Alan D. Lopez,et al.  Mortality from tobacco in developed countries: indirect estimation from national vital statistics , 1992, The Lancet.

[344]  G. Byrd,et al.  Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3'-hydroxycotinine in smokers. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[345]  C. Bonfils,et al.  Purification of two cytochrome P450 isozymes related to CYP2A and CYP3A gene families from monkey (baboon, Papio papio) liver microsomes. Cross reactivity with human forms. , 1992, European journal of biochemistry.

[346]  P. Crooks,et al.  Characterization of the glucuronide conjugate of cotinine: a previously unidentified major metabolite of nicotine in smokers' urine. , 1992, Chemical research in toxicology.

[347]  S Balabanova,et al.  [Nicotine excretion by the apocrine and eccrine sweat in smokers and passive smokers]. , 1992, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[348]  T. Aoyama,et al.  Nicotine metabolism by cDNA-expressed human cytochrome P-450s , 1992 .

[349]  P. Crooks,et al.  Inhibition of [3H]dopamine uptake into rat striatal slices by quaternary N-methylated nicotine metabolites. , 1992, Life sciences.

[350]  S. Pelletier.  Alkaloids: Chemical and Biological Perspectives , 1992, Alkaloids: Chemical and Biological Perspectives.

[351]  S. Emiliani,et al.  Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. , 1991, European journal of biochemistry.

[352]  E. Vesell,et al.  Nicotine metabolism in stumptailed macaques, Macaca arctoides. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[353]  D. Hammond,et al.  Metabolism of nicotine by rat liver cytochromes P-450. Assessment utilizing monoclonal antibodies to nicotine and cotinine. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[354]  N. Benowitz,et al.  Stable isotope studies of nicotine kinetics and bioavailability , 1991, Clinical pharmacology and therapeutics.

[355]  D. Bailey,et al.  Interaction of citrus juices with felodipine and nifedipine , 1991, The Lancet.

[356]  G. Englund,et al.  Conjugation Pathways in Nicotine Metabolism , 1991 .

[357]  Neurath Gb,et al.  Detection of Nornicotine in Human Urine after Infusion of Nicotine , 1991 .

[358]  N. Benowitz,et al.  Oxidative Metabolism of Nicotine In Vivo , 1991 .

[359]  S. Kira,et al.  Respiratory nicotine absorption in non-smoking females during passive smoking , 1991, International archives of occupational and environmental health.

[360]  E. Vesell,et al.  Disposition of nicotine and eight metabolites in smokers and nonsmokers: Identification in smokers of two metabolites that are longer lived than cotinine , 1990, Clinical pharmacology and therapeutics.

[361]  E. Vesell,et al.  Metabolism of nicotine by hepatocytes. , 1990, Biochemical pharmacology.

[362]  N. Benowitz,et al.  Synthesis of (3'R,5'S)-trans-3'-hydroxycotinine, a major metabolite of nicotine. Metabolic formation of 3'-hydroxycotinine in humans is highly stereoselective. , 1990, Journal of medicinal chemistry.

[363]  R. Obach,et al.  Radioimmunoassay of nicotine-delta 1'(5')-iminium ion, an intermediate formed during the metabolism of nicotine to cotinine. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[364]  D. Williams,et al.  The role of cytochromes P-450 and flavin-containing monooxygenase in the metabolism of (S)-nicotine by rabbit lung. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[365]  F. Gonzalez,et al.  The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. , 1990, Biochemistry.

[366]  B. Lundell,et al.  Nicotine and Cotinine Concentrations in the Nursing Mother and Her Infant , 1990, Acta paediatrica Scandinavica.

[367]  M. J. Coon,et al.  Rabbit nasal cytochrome P-450 NMa has high activity as a nicotine oxidase. , 1990, Biochemical and biophysical research communications.

[368]  I. Stolerman,et al.  Nicotine psychopharmacology : molecular, cellular, and behavioural aspects , 1990 .

[369]  N. Benowitz.  Clinical pharmacology of inhaled drugs of abuse: implications in understanding nicotine dependence. , 1990, NIDA research monograph.

[370]  D. Jacobs,et al.  Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. , 1990, American journal of public health.

[371]  S. Balabanova,et al.  [Detection of drugs in sweat]. , 1990, Beitrage zur gerichtlichen Medizin.

[372]  K. Rustemeier,et al.  Identification of cis-3'-hydroxycotinine as a urinary nicotine metabolite. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.

[373]  P. Jacob,et al.  Liver and lung microsomal metabolism of the tobacco alkaloid beta-nicotyrine. , 1989, Chemical research in toxicology.

[374]  M. Jarvik,et al.  Food and nicotine metabolism , 1989, Pharmacology Biochemistry and Behavior.

[375]  D Hoffmann,et al.  The relevance of tobacco-specific nitrosamines to human cancer. , 1989, Cancer surveys.

[376]  N. Benowitz,et al.  Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum , 1988, Clinical pharmacology and therapeutics.

[377]  M. Shigenaga,et al.  Metabolism-dependent covalent binding of (S)-[5-3H]nicotine to liver and lung microsomal macromolecules. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[378]  M. Benwell,et al.  Evidence that Tobacco Smoking Increases the Density of (−)‐[3H]Nicotine Binding Sites in Human Brain , 1988, Journal of neurochemistry.

[379]  P. Crooks,et al.  N‐Methylation of nicotine enantiomers by human liver cytosol , 1988, The Journal of pharmacy and pharmacology.

[380]  P. Crooks,et al.  Species variation and stereoselectivity in the metabolism of nicotine enantiomers. , 1988, Xenobiotica; the fate of foreign compounds in biological systems.

[381]  M. Verstraete.  Neuere Etnwicklungen in der Fibrinolyse , 1988 .

[382]  G. Neurath,et al.  Trans-3'-hydroxycotinine--a main metabolite in smokers. , 1988, Klinische Wochenschrift.

[383]  H. Muranaka,et al.  Evaluation of nicotine, cotinine, thiocyanate, carboxyhemoglobin, and expired carbon monoxide as biochemical tobacco smoke uptake parameters , 1988, International archives of occupational and environmental health.

[384]  L. Jarczyk,et al.  Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers. , 1988, Klinische Wochenschrift.

[385]  J. Palca.  Nicotine addiction , 1988, Nature.

[386]  N. Benowitz,et al.  Apparent tolerance to the acute effect of nicotine results in part from distribution kinetics. , 1987, The Journal of clinical investigation.

[387]  N. Benowitz,et al.  Influence of tobacco abstinence on the disposition kinetics and effects of nicotine , 1987, Clinical pharmacology and therapeutics.

[388]  N. Benowitz,et al.  Determinants of nicotine intake while chewing nicotine polacrilex gum , 1987, Clinical pharmacology and therapeutics.

[389]  L. Peterson,et al.  Stereochemical studies on the cytochrome P-450 catalyzed oxidation of (S)-nicotine to the (S)-nicotine delta 1'(5')-iminium species. , 1987, Journal of medicinal chemistry.

[390]  G. Neurath,et al.  Trans-3′-hydroxycotinine as a main metabolite in urine of smokers , 1987, International archives of occupational and environmental health.

[391]  N. Benowitz,et al.  Identification and quantitative analysis of cotinine-N-oxide in human urine. , 1987, Journal of chromatography.

[392]  J. Garriott,et al.  A fatal poisoning from Nicotiana glauca. , 1987, Journal of toxicology. Clinical toxicology.

[393]  G. B. Gori,et al.  Mouth versus deep airways absorption of nicotine in cigarette smokers , 1986, Pharmacology Biochemistry and Behavior.

[394]  G. B. Gori,et al.  Analytical cigarette yields as predictors of smoke bioavailability. , 1985, Regulatory toxicology and pharmacology : RTP.

[395]  N. Benowitz,et al.  Nicotine renal excretion rate influences nicotine intake during cigarette smoking. , 1985, The Journal of pharmacology and experimental therapeutics.

[396]  R. Etzel,et al.  Urine cotinine excretion in neonates exposed to tobacco smoke products in utero. , 1985, The Journal of pediatrics.

[397]  M. Noma,et al.  The alkaloid contents of sixty Nicotiana species , 1985 .

[398]  O. Pelkonen,et al.  Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and interspecies comparisons. , 1985, British journal of clinical pharmacology.

[399]  H Nau,et al.  Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. , 1985, Developmental pharmacology and therapeutics.

[400]  M. McNabb.  Chewing nicotine gum for 3 months: what happens to plasma nicotine levels? , 1984, Canadian Medical Association journal.

[401]  H Nau,et al.  Nicotine and cotinine concentrations in serum and milk of nursing smokers. , 1984, British journal of clinical pharmacology.

[402]  J. Boreham,et al.  Urinary nicotine concentrations in cigarette and pipe smokers. , 1984, Thorax.

[403]  N. Benowitz,et al.  Daily intake of nicotine during cigarette smoking , 1984, Clinical pharmacology and therapeutics.

[404]  R. Solomon,et al.  Elevated nicotine levels in patients undergoing hemodialysis. A role in cardiovascular mortality and morbidity? , 1984, The American journal of medicine.

[405]  N. Benowitz,et al.  Cotinine disposition and effects , 1983, Clinical pharmacology and therapeutics.

[406]  R. Herning,et al.  Smokers of low-yield cigarettes do not consume less nicotine. , 1983, The New England journal of medicine.

[407]  N. Benowitz,et al.  Circadian blood nicotine concentrations during cigarette smoking , 1982, Clinical pharmacology and therapeutics.

[408]  P. Slanina,et al.  Nicotyrine inhibits in vivo metabolism of nicotine without increasing its toxicity. , 1982, Toxicology and applied pharmacology.

[409]  R. Ebert,et al.  Plasma nicotine levels produced by chewing nicotine gum. , 1982, JAMA.

[410]  K. McCusker,et al.  Plasma nicotine levels in pipe smokers. , 1982, JAMA.

[411]  R T Jones,et al.  Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. , 1982, The Journal of pharmacology and experimental therapeutics.

[412]  J. Gorrod,et al.  The metabolism of nicotine-delta 1'(5')-iminium ion, in vivo and in vitro. , 1982, European journal of drug metabolism and pharmacokinetics.

[413]  H. Schievelbein.  Nicotine, resorption and fate. , 1982, Pharmacology & therapeutics.

[414]  N. Wald,et al.  SERUM COTININE LEVELS IN PIPE SMOKERS: EVIDENCE AGAINST NICOTINE AS CAUSE OF CORONARY HEART DISEASE , 1981, The Lancet.

[415]  H. Ar,et al.  Nicotine delta 1 "(5)' iminium ion: a reactive intermediate in nicotine metabolism. , 1981 .

[416]  J. Gorrod,et al.  Nicotine delta 1 "(5)' iminium ion: a reactive intermediate in nicotine metabolism. , 1981, Advances in experimental medicine and biology.

[417]  M A Russell,et al.  Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers. , 1980, British medical journal.

[418]  L. Lindblom,et al.  The enzyme “aldehyde oxidase” is an iminium oxidase. Reaction with nicotine Δ1′(5′) iminium ion , 1979 .

[419]  L. Lindblom,et al.  SYNTHESIS, STRUCTURE AND STABILITY OF NICOTINE Δ1′(5′) IMINIUM ION, AN INTERMEDIARY METABOLITE OF NICOTINE , 1979 .

[420]  K. Lempert,et al.  Synthesis, Structure and Stability of Nicotine Delta1'(5') Iminium Ion, an Intermediary Metabolite of Nicotine. , 1979 .

[421]  L. Gruenke,et al.  Metabolic oxidation of nicotine to chemically reactive intermediates. , 1979, Journal of medicinal chemistry.

[422]  L. Lindblom,et al.  The enzyme "aldehyde oxidase" is an iminium oxidase. Reaction with nicotine delta 1'(5') iminium ion. , 1979, Biochemical and biophysical research communications.

[423]  C. Dollery,et al.  Absorption of nicotine from small cigars , 1978, Clinical pharmacology and therapeutics.

[424]  R. Scheline.  Mammalian metabolism of plant xenobiotics , 1978 .

[425]  C. Feyerabend,et al.  Cigarette smoking: a dependence on high-nicotine boli. , 1978, Drug metabolism reviews.

[426]  M. Mcnicol,et al.  Effect of cigar smoking on carboxyhaemoglobin and plasma nicotine concentrations in primary pipe and cigar smokers and ex-cigarette smokers , 1977, British medical journal.

[427]  E. Bowman,et al.  The interrelationship between the metabolism of (S)-continine-N-oxide and (S)-cotinine. , 1977, Drug metabolism and disposition: the biological fate of chemicals.

[428]  D. Hoffmann,et al.  Nitrogen-containing compounds in tobacco and tobacco smoke. , 1977 .

[429]  S. Soloway.  Naturally occurring insecticides. , 1976, Environmental health perspectives.

[430]  A. Poole,et al.  The metabolism of (14C)nicotine by isolated rhesus monkey hepatocytes in vitro. , 1976, Biochemical pharmacology.

[431]  C. Dollery,et al.  Absorption and metabolism of nicotine from cigarettes. , 1975, British medical journal.

[432]  A. Beckett,et al.  Reduction in vivo of (−)-nicotine-1′-N-oxide by germ-free and conventional rats , 1975 .

[433]  P. Jenner,et al.  The metabolism of tobacco alkaloids , 1975 .

[434]  A. Beckett,et al.  Reduction in vivo of (minus)-nicotine-1'-N-oxide by germ-free and conventional rats. , 1975, Biochemical pharmacology.

[435]  H. Harke,et al.  Demethylation of nicotine and cotinine in pigs. , 1974, Research communications in chemical pathology and pharmacology.

[436]  D Hoffmann,et al.  The pH of tobacco smoke. , 1974, Food and cosmetics toxicology.

[437]  Beckett Ah,et al.  Proceedings: In vitro metabolic N-oxidation of the minor tobacco alkaloids, (-)methylanabasine and (-)anabasine to yield a hydroxylamine and a nitrone in lung and liver homogenates. , 1973 .

[438]  P. Jenner,et al.  Comparative in vitro hepatic metabolism of some tertiary N-methyl tobacco alkaloids in various species. , 1973, Research communications in chemical pathology and pharmacology.

[439]  P. Jenner,et al.  Species Variation in the Metabolism of R-(+)- and S-(-)-Nicotine by α-C- and N-Oxidation in vitro , 1973 .

[440]  P. Murphy.  Enzymatic oxidation of nicotine to nicotine 1'(5') iminium ion. A newly discovered intermediate in the metabolism of nicotine. , 1973, The Journal of biological chemistry.

[441]  D. Hutson.  Biological Oxidation of Nitrogen in Organic Molecules , 1973 .

[442]  A. Beckett,et al.  Proceedings: In vitro metabolic N-oxidation of the minor tobacco alkaloids, (-)methylanabasine and (-)anabasine to yield a hydroxylamine and a nitrone in lung and liver homogenates. , 1973, The Journal of pharmacy and pharmacology.

[443]  P. Jenner,et al.  Species variation in the metabolism of R-(+)- and S-(-)-nicotine by alpha-C- and N-oxidation in vitro. , 1973, Xenobiotica; the fate of foreign compounds in biological systems.

[444]  P. Jenner,et al.  A possible relation between pKa1 and lipid solubility and the amounts excreted in urine of some tobacco alkaloids given to man , 1972, The Journal of pharmacy and pharmacology.

[445]  P. Jenner,et al.  Absorption of (−)‐nicotine‐1′‐N‐oxide in man and its reduction in the gastrointestinal tract , 1970, The Journal of pharmacy and pharmacology.

[446]  W. Hayes,et al.  Essays in toxicology , 1969 .

[447]  va Grusz-Harday.  Tdliche Nicotinvergiftungen@@@Fatal nicotine poisoning , 1967 .

[448]  E. Grusz-Harday.  [Fatal nicotine poisoning]. , 1967, Archiv fur Toxikologie.

[449]  S. Vanov,et al.  Comparison of pharmacological activity of nicotine and related alkaloids occurring in cigarette smoke. , 1965, Archives internationales de pharmacodynamie et de therapie.

[450]  S. Schwartz,et al.  ALTERNATE ROUTES IN THE METABOLIC DEGRADATION OF THE PYRROLIDINE RING OF NICOTINE. , 1964, The Journal of biological chemistry.

[451]  N. Papadopoulos.  FORMATION OF NORNICOTINE AND OTHER METABOLITES FROM NICOTINE IN VITRO AND IN VIVO. , 1964, Canadian journal of biochemistry.

[452]  R. Pinsent,et al.  A DESIGN FOR GENERAL PRACTICE. I. REINFORCEMENT FOR THE FAMILY DOCTOR. , 1963, Lancet.

[453]  L. Turnbull,et al.  The Synthesis of Hydroxycotinine and Studies on Its Structure1 , 1963 .

[454]  L. Turnbull,et al.  N-Methylation of nicotine ad cotinine in vivo. , 1963, The Journal of biological chemistry.

[455]  S. Schwartz,et al.  The Corrected Structure of a Ketoamide Arising from the Metabolism of (-)-Nicotine , 1962 .

[456]  E. Bowman,et al.  Studies on the metabolism of (-)-cotinine in the human. , 1962, The Journal of pharmacology and experimental therapeutics.

[457]  L. Turnbull,et al.  Norcotinine (desmethylcotinine) as a urinary metabolite of nornicotine. , 1961, Journal of medicinal and pharmaceutical chemistry.

[458]  L. Turnbull,et al.  Metabolism of nicotine in the human and excretion of pyridine compounds by smokers. , 1959, The Journal of pharmacology and experimental therapeutics.